Explore

Rapid ReadRapid Read
Vanderbilt-Ingram Cancer Center Unveils Comprehensive Transcriptomic Atlas to Enhance Breast Cancer Treatment Precision

Vanderbilt-Ingram Cancer Center Unveils Comprehensive Transcriptomic Atlas to Enhance Breast Cancer Treatment Precision

Researchers at Vanderbilt-Ingram Cancer Center have developed one of the largest transcriptomic maps of breast cancer to date. This comprehensive atlas, detailed in Cell Reports Medicine, integrates 7,612 breast cancer transcriptomes from 22 independent datasets, providing an unprecedented view of the disease's molecular diversity. The team, led by Brian Lehmann, PhD, Research Associate Professor of Medicine, identified 12 breast cancer-intrinsic subtypes and three major tumor microenvironment programs, collectively named the integrated Breast Cancer Transcriptome Classification (iBTC). This atlas reveals previously unrecognized forms of breast cancer with distinct prognoses, biological characteristics, and therapeutic vulnerabilities, moving beyond traditional classifications to enable more precise and effective treatment decisions.
TrendlineTrendline
Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials

Immunome Reports Strong Q3 2026 Financial Results and Advances Oncology Pipeline with New Clinical Trials
TrendlineTrendline
101 Therapeutics Presents Macrophage-Targeted Glucocorticoid 101-PGC-005 Data at ACR Convergence 2026

101 Therapeutics Presents Macrophage-Targeted Glucocorticoid 101-PGC-005 Data at ACR Convergence 2026

101 Therapeutics Presents Macrophage-Targeted Glucocorticoid 101-PGC-005 Data at ACR Convergence 2026
TrendlineTrendline
Olema Oncology Reports Third Quarter 2026 Financial Results and Advances Breast Cancer Therapies

Olema Oncology Reports Third Quarter 2026 Financial Results and Advances Breast Cancer Therapies

Olema Oncology Reports Third Quarter 2026 Financial Results and Advances Breast Cancer Therapies
TrendlineTrendline
AstraZeneca Seeks AI Research Director to Transform Oncology Clinical Development

AstraZeneca Seeks AI Research Director to Transform Oncology Clinical Development

AstraZeneca Seeks AI Research Director to Transform Oncology Clinical Development
TrendlineTrendline
ImmunityBio Reports Expanded FDA Approval for ANKTIVA and Strong Q3 2026 Revenue Growth

ImmunityBio Reports Expanded FDA Approval for ANKTIVA and Strong Q3 2026 Revenue Growth

ImmunityBio Reports Expanded FDA Approval for ANKTIVA and Strong Q3 2026 Revenue Growth
Rapid ReadRapid Read
UCLA-Led Study Develops Clinical-Scale CRISPR Gene Correction for Sickle Cell Disease

UCLA-Led Study Develops Clinical-Scale CRISPR Gene Correction for Sickle Cell Disease

A new study has demonstrated the successful development of a clinical-scale manufacturing process capable of directly correcting the mutation responsible for sickle cell disease (SCD) in patients’ blood-forming stem cells. The experimental therapy, named CRISPR_SCD001, utilizes CRISPR-Cas9 technology along with a short, single-stranded DNA template to repair the sickle mutation within the beta-globin gene (HBB). The process involves collecting CD34-positive cells from mobilized peripheral blood, culturing them, and then using electroporation to introduce the CRISPR-Cas9 complex and corrective DNA template. These edited autologous cells are then intended for reinfusion into the patient after conditioning. This approach differs from currently approved gene therapies for SCD, which either add an anti-sickling gene via a lentiviral vector or edit a regulatory region to restore fetal hemoglobin production. CRISPR_SCD001 aims to directly repair the disease-causing mutation without a viral donor template. The man...
Rapid ReadRapid Read
Lee Kun-hee's Donation Drives Breakthroughs in Pediatric Cancer and Rare Disease Treatment in Korea

Lee Kun-hee's Donation Drives Breakthroughs in Pediatric Cancer and Rare Disease Treatment in Korea

A 300 billion won donation from the family of the late Samsung Electronics Chairman Lee Kun-hee to Seoul National University Children's Hospital five years ago has yielded significant results in combating childhood cancer and rare diseases. The initiative, known as the 'Lee Kun-hee Childhood Cancer and Rare Disease Overcoming Project,' has led to the diagnosis of 22,646 patients and treatment of 14,757 as of September. Key achievements include the establishment of Korea's first standard treatment protocol for pediatric acute lymphoblastic leukemia, which classifies patients into five risk groups using genome analysis and next-generation sequencing. Additionally, the project has discovered and diagnosed over 20 new types of previously unknown rare diseases. A national rare disease diagnosis network has been created, enabling regional hospitals to send samples to a central analysis center for diagnostic results within four to six weeks. The research collaboration system has also expanded, with supported proj...
TrendlineTrendline
Precision for Medicine Seeks Resource Manager to Optimize Oncology Development Pathway

Precision for Medicine Seeks Resource Manager to Optimize Oncology Development Pathway

Precision for Medicine Seeks Resource Manager to Optimize Oncology Development Pathway
Rapid ReadRapid Read
City of Hope Researchers Develop Novel Microbiome Therapy to Prevent Bloodstream Infections in Cancer Patients

City of Hope Researchers Develop Novel Microbiome Therapy to Prevent Bloodstream Infections in Cancer Patients

Researchers at City of Hope, in collaboration with Memorial Sloan Kettering Cancer Center and Seres Therapeutics, have developed a new microbiome therapy, SER-155, aimed at preventing dangerous bloodstream infections in patients undergoing donor stem cell transplants for blood cancers. This first-of-its-kind therapy delivers 16 carefully selected beneficial bacteria designed to restore the microbiome and combat harmful pathogens. In a multicenter phase 1 clinical trial, SER-155 was found to be well tolerated with no treatment-related side effects. Patients who received the therapy experienced fewer bloodstream infections and lower levels of harmful bacteria associated with infection. The study, published in Nature Medicine, provides early evidence that live biotherapeutics, which are medicines made from beneficial bacteria, can be safely administered to highly vulnerable patients and may help prevent serious infections. This approach represents a significant step towards engineering the microbiome for spec...
Rapid ReadRapid Read
BYU Researchers Develop MOTO-CAR Immunotherapy for Difficult-to-Cure Cancers

BYU Researchers Develop MOTO-CAR Immunotherapy for Difficult-to-Cure Cancers

Researchers at Brigham Young University (BYU) have developed a new immunotechnology called MOTO-CAR, which genetically engineers macrophages to recognize and attack cancer cells. This technology aims to convert a patient's own immune system into a cancer-fighting mechanism. According to lead researcher and BYU professor of microbiology and molecular biology Kim O'Neill, this method could lead to new treatments for cancers that are currently difficult to cure, such as glioblastoma, triple-negative breast cancer, and pancreatic cancer. Preclinical trials have shown promising results; in one in vitro study, a 90% reduction in aggressive lung cancer cells was observed within 24 hours. Another study in mice demonstrated a reduction in tumor sizes by up to 46% with a single treatment regimen. The process involves identifying cancer biomarkers from a tumor biopsy, selecting a pre-engineered MOTO-CAR therapeutic, and administering it via infusion. The research is currently in the preclinical stage, and further fun...
TrendlineTrendline
QUANTRO Therapeutics Secures Austrian Grant to Advance AI-Powered Drug Discovery Platform

QUANTRO Therapeutics Secures Austrian Grant to Advance AI-Powered Drug Discovery Platform

QUANTRO Therapeutics Secures Austrian Grant to Advance AI-Powered Drug Discovery Platform